Nephros, Inc. (NEPH) CEO Andy Astor on Q4 2020 Results - Earnings Call Transcript

Nephros, Inc. (NASDAQ:NEPH) Q4 2020 Earnings Conference Call March 1, 2021 4:30 PM ET

Company Participants

Kirin Smith - PCG Advisory Group, Investor Relations

Andy Astor - Chief Executive Officer

Wes Lobo - Chief Marketing Officer

Conference Call Participants

Marc Wiesenberger - B Riley FBR

Anthony Vendetti - Maxim Group

Operator

Good afternoon. And welcome to the Nephros Incorporated Fourth Quarter 2020 Financial Results Conference Call. All participants will be in listen-only mode. [Operator Instructions] After today's presentation, there will be an opportunity to ask questions. [Operator Instructions] Please note, this event is being recorded.

I would now like to turn the conference over to Kirin Smith, Investor Relations. Please go ahead.

Kirin Smith

Good afternoon, everyone. This is Kirin Smith with PCG Advisory. Thank you all for participating in Nephros’ full year 2020 conference call.

Before we begin, I would like to caution that comments made during this conference call by management will contain forward-looking statements regarding the operations and future results of Nephros.

I encourage you to review Nephros’ filings with the Securities and Exchange Commission, including without limitation, the company’s Forms 10-K and 10-Q, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.

Factors that may affect the company’s results include, but are not limited to, its ability to successfully, timely, and cost effectively develop, seek, and obtain regulatory clearance for and commercialize its products and service offerings, the rate of adoption of its products and services by hospitals and other healthcare providers, the success of its commercialization efforts, the effect on its business of existing and new regulatory requirements, and other economic and competitive factors.

The content of this conference call contains time-sensitive information that is accurate only as of the date of the live call, today, March 1, 2021. The company undertakes no obligation to revise or update any statements to reflect events or circumstances after the date of this conference call, except as required by law.

I would now like to turn the call over to Andy Astor, Nephros’ CEO. Andy, please go ahead.

Andy Astor

Thank you, Kirin. Good afternoon everyone. I'll spend a few minutes reviewing our business operations and then turn my attention to the company's financial performance. But first, as with all of our earnings calls in these pandemic times, I'd like to express my gratitude to all of the essential workers who continue to keep our country moving at our fellow citizens safe.

As you are aware, our business takes us into these health care facilities, where we provide products and services to keep healthcare workers and patients safe. And to that point, I would also like to extend a sincere thank you to all of our Nephros’ employees and our partners and distributors for continuing to provide excellent service and support through an incredibly difficult 2020 and into 2021.

Now, onto our results. I will begin with our water filtration core business segment, and candidly, the water the Nephros water filtration business had a challenging year in 2020. After 15 consecutive quarters of revenue growth, averaging 60%, sales in 2020 were down 17% compared to 2019, while cash burn and net losses increased.

The 2020 revenue downturn was driven by the COVID-19 pandemic and it manifested itself primarily in three ways. First was a reduction in our emergency response business. This was the business, in which we respond with filtration solutions to outbreaks of water pathogens and associated disease. The reduction of this business appears to have been an industry-wide pattern, driven by healthcare institutions being focused primarily on COVID-19 during the year.

The second major contributor to the revenue downturn was the reduction in the new business as access -- I’m sorry, as accessibility to facilities and new customers in our core markets were significantly restricted due to COVID-19.

And the third and final trend contributing to revenue reduction was the downturn in the restaurant and hotel industries, which are the -- of course the target markets of our commercial filtration solution. These negative trends, however, were offset by very stable recurring revenue from our existing customer base, largely maintaining levels from prior years and limiting our overall downturn for the year.

Accordingly, looking past the pandemic, I strongly believe the Nephros Water Filtration business is a promising one. From 2016 to 2019, this segment grew 345%, and did so consistently quarter-after-quarter-after-quarter. Furthermore, the segment turned profitable in Q4 2019, the quarter before the pandemic hit.

As a pandemic recedes over the coming few quarters, we believe this segment can return to the high growth levels of the previous four years, and do so profitably. And to reap the benefits of this opportunity, we will continue to invest in both our medical and commercial core business most significantly in sales and marketing.

One of our top priorities will be to drive market awareness of our filtration solutions and to generate demand. These will be a primary focused area for Wes Lobo, our new Chief Marketing Officer and his organization, and I'll introduce Wes in a moment for some brief introductory comments.

Wes joined Nephros in mid-February, after recently serving as Vice President of Marketing and New Product Development at Watts Water Technologies, a leader in plumbing, heating and water quality products and services for residential, commercial, and general industrial markets. Wes brings more than 20 years of water industry expert -- experience and expertise in commercial roles of increasing responsibility, including sales, marketing, business development, strategy, and customer service.

He holds a Bachelor of Science in Chemical Engineering from Lafayette College and a Master of Business Administration from the Duke University Fuqua School of Business. Wes is a certified Lean Six Sigma Black Belt and a graduate of the Xylem Executive Development Program.

So I would now like to pause for a moment, and let Wes introduce himself. Wes?

Wes Lobo

Thank you, Andy. It is a pleasure to be here and thank you for allowing me a moment to introduce myself to the investor community.

First, I would like to echo, how Andy kicked off this call. Amazingly, we've now been living in a pandemic stricken world for over a year, and we look forward to return to normalcy and hopefully not too distant future.

Over this past year, we have seen our nation’s essential workers, our everyday heroes; continue to answer the bell day-in and day-out. We owe them a debt of gratitude and our continued support for what they have done, are doing, and will continue to do post-pandemic.

So why did I joined Nephros? I am passionate about the water industry, and I've had the privilege to serve within this community for over 20 years. Through my early discussions with Andy and the management team, two things became clear; one, Nephros is a company founded on industry leading science and technology for water safety through purification and pathogen detection; two, and more importantly, Nephros is a diverse and passionate team dedicated to helping people.

The combination of these two attributes positions the company for accelerated growth as was demonstrated for 15 consecutive quarters, prior to the COVID-19 pandemic. The pandemic has raised awareness on the topic of pathogens be the airborne or waterborne. At Nephros, we have the opportunity and the obligation to partner with communities and facilities to educate, monitor and treat for waterborne pathogens.

When your mission is to help people by advancing water safety, it is easy to have a common sense of purpose. I'm humbled and honored to be given the opportunity to tell the Nephros’s story, work with this incredible team, and help unlock the Nephros’s growth potential to be a company that does well by doing good. Thank you.

Andy Astor

Thank you, Wes. We're excited to have you. One more thing regarding the Water Filtration Business segment, I mentioned the medical side. On the commercial side, we continue to pursue large contracts with major brand names in the food service space. And while this process has taken frankly much longer than expected, due to previously mentioned slowness in the space, we remain optimistic about these opportunities within our Commercial Filtration segment.

I'll turn my attention to Pathogen Detection Systems, or PDS our second business segment. 2020 was our first year recognizing the segment and first year revenues were quite small. Fundamentally, as was also true in the filtration business, development of new business relationships and sales of new products proved very challenging in 2020, due to the single-minded market focus on COVID-19 related topics within the healthcare community.

While we're off to a slow start, we remain very optimistic about this business. We committed significant resources during 2020, building an infrastructure, including the initial release of three new products, implementation of a Level 2 Biosafety laboratory, installation of an automated manufacturing system, and the development of significant scientific papers and marketing materials.

We expect PDFs to be a vital part of the healthcare facilities – I'm sorry, of healthcare facilities water management practices, enabling them to conduct onsite measurement and detection of waterborne pathogens, such as legionella. With proactive monitoring and potentially leveraging point of view filtration as necessary, our aim is to mitigate potential waterborne pathogen outbreaks from legionella and pseudomonas and E. coli and many others.

As markets reopen in the second half of 2021 and early 2022, we expect to see significant revenue growth within the segment, like water filtration, PDS will be a major focus for our new marketing organization, as well as the rest of the Nephros’s team.

I'll briefly give an update on HDF, or Hemodiafiltration business segment, which is a majority owned -- in our majority owned subsidiary specialty rental products, in which we are pleased to report that we have completed the development of the second generation HDF product, and we have begun conversations with the FDA regarding the 510(k) clearance process. We expect to announce formal submission acceptance and expected timelines in the very near future. Once we receive FDA clearance, we will work to identify a few dialysis clinics to take part in our soft-launch, which we expect to initiate in the second half of 2021.

I'll now provide a few highlights of our Q4 and full-year financial performance. Nephros reported net revenues in the fourth quarter of $2.3 million, a 10% increase over third quarter of 2020, and a 26% decrease versus fourth quarter of 2019. For the full year, net revenues were $8.6 million, a 17% decrement, when compared to $10.3 million in 2019.

While net revenues were down year-over-year, as I alluded to earlier, I'm pleased to note that fourth quarter revenues from our recurring installed base remained at 2019 levels. We believe that this strong demand from existing customers is an important sign of the underlying strength of our business, bolstered by our customer retention rate of about 90%.

As a reminder, we recognize three distinct business segments, water filtration, pathogen detection and renal products, of course, and all of the revenues that I just described were generated by the water filtration business segment.

Net loss in the water filtration business segment was $0.3 million, compared with net income of $0.2 million in 2019. For the full year, water filtration showed a net loss of $2.2 million compared to $1.1 million in 2019. This increased loss was due primarily to the reduced revenue I discussed earlier.

Adjusted EBITDA in the water filtration segment for the fourth quarter was approximately breakeven, compared to positive $0.7 million in the same quarter 2019. Adjusted EBITDA in the water filtration segment for the full year was negative $1.4 million, compared with positive $0.5 million in 2019.

Please refer to today's press release for more details about the calculation of adjusted EBITDA and its reconciliation to GAAP net income or loss. Additional information about the water filtration, pathogen detection and renal products business segments and their operating results can be found in today's filing on Form 10-K.

On a consolidated basis, net loss for the quarter was $0.8 million, compared with $0.1 million in 2019. For the full year, net loss was $4.5 million, compared with $3.2 million in 2019. And, once again, the increased loss was almost entirely due to reduced revenues and the associated reduction in gross margin available to cover other costs.

Consolidated adjusted EBITDA in the quarter was negative $0.5 million, compared with positive $0.4 million in 2019. And for the full year, consolidated adjusted EBITDA was negative $3.6 million, compared with negative $1.2 million in 2019.

Cost of goods sold in the fourth quarter was $1.0 million, compared with $1.3 million in 2019. Cost of goods sold for the year was $3.6 million, compared with $4.3 million in 2019.

Gross Margin percentages for the fourth quarter were 56% compared with 60% in 2019. Gross margins for the year were 57%, compared with 59% in 2019. And as we have said, almost every -- I think every quarter over the last few years, we expect our gross margins to continue in the range of 55% to 60%

Research and development, or R&D, expenses in the fourth quarter were $0.6 million, compared with $0.8 million in 2019. R&D expenses for the year were $2.8 million compared with $3.1 million in 2019.

Depreciation and amortization expenses in the fourth quarter were $50,000 compared with $44,000 in 2019. And for the year, depreciation and amortization were $0.2 million both in 2020 and in 2019.

Selling, general and administrative or SG&A expenses for the fourth quarter will $1.4 million in both 2020 and 2019 and for the year, SG&A expenses were $6.5 million compared with $6.1 million in 2019. Our cash balance at the end of 2020 was about $8.2 million and as you may be aware in October of 2020, we completed a common stock offering which generated approximately $4.7 million of net cash proceeds.

In closing, all of us at Nephros want to once again thanks to health care and other frontline professionals providing essential services that keep our fellow citizens safe. Let me also mention that we will be at several financial conferences this spring, details of which will be released publicly as well as to our mailing list. I look forward to seeing many of you these shows virtually in all likelihood.

Also, if you're not already subscribed to our occasional email alerts, you may do so at the bottom of our website homepage. And of course, please always feel free to contact me directly at [e-mail].

This concludes our formal presentation remarks. I would like to personally thank all of our investors and other stakeholders for your support through the years. I look forward to speaking with you all again soon.

And we'll take questions now from the audience, and also answer emailed questions, if there are any. Operator, please open the call for questions.

Question-and-Answer Session

We will now begin the question-and-answer session. [Operator Instruction] Our first question comes from Marc Wiesenberger with B Riley FBR. Please go ahead.

Q - Marc Wiesenberger

Yeah. Thank you. Good afternoon. Can you talk about what you're hearing from your distribution partners on the ground, and what's their ability to get access to hospitals and healthcare facilities and how is that evolved from the end of last year into 2021 so far?

Andy Astor

Marc, first of all, thanks for the question. It's good to hear from you. I would say that the comparison between Q1 of 2021 and Q4 of 2020 is analogous to the comparison of 20 -- Q4 2020 to Q3 2020. In other words, it's a steady slow reopening. If I had to project, I think you're going to see a pretty steady slope of that line.

And this is also what I'm hearing from our partners that we're going to see a pretty steady slope of that line Q4, Q1, Q2. And then we would expect the slope of the line to increase in the second half of the year when most of the population -- when the vaccine is more widely distributed.

But I would call…

Marc Wiesenberger

Understood.

Andy Astor

If I were to put a final point on it, a quarter ago if you had asked me, I would say the market was about 90% closed and I would say, it's still about 80% closed.

Marc Wiesenberger

Understood. Thank you. I know that the outbreak response business has some seasonality with usually higher activity in the warmer months, but are you at least seeing customers and facility managers starting to at least refocus their priorities and undertake maybe more normalized levels of testing and monitoring, which could bode well for kind of bounce back in that business?

Andy Astor

A little. We are definitely seeing some emergency response events and servicing them, of course. But I would say that that bounce back is slow, but it does appear to be beginning.

Marc Wiesenberger

Okay, understood. Also, as schools are starting to return to more in-person learning, you've had districts in Michigan, Ohio, Pennsylvania, New York report elevated levels of Legionella in their drinking water following the closures. And then even recently the Governor of Wisconsin in her budget proposal, put $55 million in there to install water filters in schools statewide across Wisconsin. How should we think about Nephros potentially expanding its opportunities into schools, and maybe other markets that it has not traditionally served?

Andy Astor

Great question. Thank you. What I would say is Nephros is 90% an indirect selling company that sells through the water service treatment professionals that are our strategic partners. And so, it is really a matter of making sure that we partner with as many of the best of those that we can.

Now, we've already serviced multiple school systems including some locally in New Jersey. But it really is a matter of working through our partners, our distributors who have those relationships. The Nephros sales model is not to hire up sales force of 100 people, but rather to go to support with expert sales and product capabilities the distributors that we are partnered with, and so I would expect that not to change fundamentally.

Marc Wiesenberger

Understood, and last one for me. Where do we stand on some of the commercial RFPs that have been in the pipeline? And maybe if you could just give an update on some of the give and takes on what's going on with the negotiations, and maybe even we could expect to hear some good news there? Thank you very much.

Andy Astor

Thank you, Marc. I'd be happy to tell you all about the give and take except that it's mostly give. And what I mean by that is that we are dealing with extremely large organizations, and they move at their own pace. And while, as I said in my prepared remarks, we remain optimistic on those opportunities.

We were premature, obviously, to talk about them, probably at this point, nine months ago. They are still developing. They are still developing in a helpful way. And, I cannot give you more specific guidance as to when they will close. But they're larger opportunities and will make a difference when they do.

Marc Wiesenberger

Great. Thank you very much.

Andy Astor

My pleasure. Thank you, Marc.

Operator

Excuse me. The next question is from Anthony Vendetti with Maxim Group. Please go ahead.

Anthony Vendetti

Thanks. Thanks Andy, and welcome aboard Wes. Andy just a quick follow-up on that, and I know that QSR has been discussed for a while, and I'm sure COVID had a lot to do with it. But would you say that pipeline though, is it the same or even though it hasn't one hasn't closed, it has the pipeline started to increase, in other words the opportunities have they expanded or is it about the same-store?

Andy Astor

Good to hear from you, Anthony. And what I would say is they have increased.

These are large opportunities, having a conversation with one organization within a large company often brings additional conversations and we are seeing that. So I think it's fair to say that the opportunities are increasing. And it's just a matter of when they fall.

Anthony Vendetti

Sure, sure. Understood. And then just on. I know the pathogen detection is new and this was obviously a difficult year ago to launch it. How do you – how should we look at that in 2021 with as you mentioned, 80% of hospitals still difficult to access, is that you think pushed out more towards the second half of this year? How should we look at it?

Andy Astor

Well, the way I look at – the way I think about the year is that the first half of the year is likely to look a lot more like 2020 than 2019. And what I mean by that is that 2020 was the peak of the pandemic and even though the vaccines came out in November, December, distribution on the time associated with it I think gets us to at least July 1 until the system fundamentally changes. And so, I'm hopeful that Q3, Q4 look more like 2019 than 2020, when we were growing 60 – 60% on average, but some quarters we're closer to 100% year-on-year.

And I'm hopeful that to see the growth curves coming back then, and when they do, I would think that pathogen detection will be part of that growth curve. So long – slightly long answer to say that I do think that you'll start to see acceleration in the second half of the year. Although, there could be some blue birds in the first half as well.

Anthony Vendetti

Okay. No, that color is helpful. Just lastly, then you mentioned that you completed the second generation, Hemodialtration system, HDF device. In terms of actual submission of that 510(k), is that on target for end of 2021 or is could that be sooner?

Andy Astor

I'm sorry, when you say this on target for 2021, do you mean the approval?

Anthony Vendetti

Yes. What do you think, what's the timeframe, is your best guess?

Andy Astor

Well, we said – as we've talked about before, we have filed the package under the special 510(k) pathway. And if assuming that the FDA accepts it, it's 30 – it's – the official timeline is 30 days once they accept it for that review. So even if they -- even if it takes time, a little extra time for whatever reason, I think that, unless there's a surprise and they don't accept it on the special 510(k) pathway. I would think it would be approved by the middle of the year.

Now, if the FDA turns around themselves. No, we think this is more of a traditional 510(k) pathway then it'll take longer. But end of year would be a surprise for me. I think it'll be long before that.

Anthony Vendetti

Right. Okay. Make sense. So special 510(k), if it's accepted, you'll find out soon, I guess. And, if not, then it would go this normal 510(k) route, which would give them 90 days to respond --

Andy Astor

Correct.

Anthony Vendetti

…once you -- you'd have to resubmit right, for regular 510(k)?

Andy Astor

We would. But we've completed all the testing and documentation required for that. So it's a large paperwork exercise, but it's only a paperwork exercise. So it would be -- if we had to go the traditional route, it would be measured in weeks, not months or years.

Anthony Vendetti

Okay, great. Thanks very much. I'll hop back in the queue.

Andy Astor

Okay. Thanks, Anthony.

Operator

The next question is from Henry Linc [ph], a private investor. Please go ahead.

Unidentified Analyst

Hi Andy. How are you?

Andy Astor

I'm good Henry. Nice to hear from you.

Unidentified Analyst

Good. Good to hear from you. And Wes, welcome on board. I'm glad to hear you’re there.

Wes Lobo

Thank you.

Unidentified Analyst

Anyway, I just was wondering, do you have projections for the pathogen detection and testing portion to go out or, how are they, going relative to projections?

Andy Astor

Well, we were not public with guidance on any of our businesses right now, Henry. But I would say that the work that's going on is going great.

And by that, I mean the development of the technology and the validation of it, and the products that we've published -- that we that we released, I’m sorry, as well as the construction of a, -- as I said a level two biosafety lab and an automated production facility.

These are all things that we've built at relatively low capital costs by the way, and are getting ready for that business to really grow. But until the healthcare markets, open up again, it's just hard to project specific revenue levels. But I'm anxious to do so as soon as we see the markets open up.

Unidentified Analyst

And you released the testing analysis, is it white papers or anything like that?

Andy Astor

We have, we have. We actually produced a prepublication white paper. Actually it was an academic paper, I guess, probably four or five months ago, talking about our SequaPath product. And we've got other papers in the works as well, so yes.

Unidentified Analyst

Right. Thank you.

Andy Astor

My pleasure, Henry.

Operator

[Operator Instructions] The next question is from Joseph Schuler [ph] with JAS Investors. Please go ahead.

Unidentified Analyst

Hi, Andy.

Andy Astor

Hey, Joe.

Unidentified Analyst

Yeah. Hi. HDF, maybe you could give us, maybe kind of elaborate a little more. You did mention that you've completed a second generation product. You also mentioned, if I heard correctly, that you're proceeding with FDA paperwork, and I think you hoping to pre-test or early markets the product possibly in the second half of 2021. I don't know, if I got that all right, but maybe you could elaborate a little bit.

Andy Astor

Well, the short answer Joe is you got it exactly right. The product is done. The paperwork for submission is done. The FDA has received it. We have a case number. We are in discussions with them over whether it's a special 510 (k) or traditional. And over the course of the next one to few months, we expect to get that product approved, that is, that's our goal. That -- and we'll have more to say as – more specifics about the submission pathway as soon as we have it from the FDA.

Unidentified Analyst

Let me just proceed with that, if assuming your best hope and it may not happens and you get the FDA approval in three months, when after that do you think you'd have a marketable product or -- mark a product on the market, let's say?

Andy Astor

Well, we'd go immediately to dialysis clinics and roll it out in a controlled number of them. So, that we could get real-world experience, but it would be -- officially, it's on the market as soon as the FDA clears it.

Unidentified Analyst

Got you. Good. Thank you very much.

Andy Astor

My pleasure. Good to hear from you, Joe.

Operator

This concludes our question and answer session, and the conference is also now concluded. Thank you for attending today's presentation. You may now disconnect.